cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2020-2532cardiovascular-2532Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEW ARTICLESСемейная гиперхолестеринемия: современное состояние проблемы и лечебно-профилактическая помощьFamilial hypercholesterolemia: current status of the problem, treatment, and preventionhttps://orcid.org/0000-0002-2619-1592БлизнюкС. А.BliznyukS. A.

Светлана Александровна Близнюк — младший научный сотрудник отдела реабилитации и вторичной профилактики сердечно-сосудистых заболеваний.

Москва, Тел.: +7 (906) 794-72-74

Moscow

Sabliznyuk@mail.ruhttps://orcid.org/0000-0003-2250-5942БубноваМ. Г.BubnovaM. G.

Марина Геннадьевна Бубнова — руководитель отдела реабилитации и вторичной профилактики сердечно-сосудистых заболеваний

Москва

Moscow

mbubnova@gnicpm.ruhttps://orcid.org/0000-0002-1518-6552ЕжовМ. В.EzhovM. V.

Марат Владиславович Ежов — главный научный сотрудник отдела проблем атеросклероза НИИ клинической кардиологии им. А.Л. Мясникова.

Москва

Moscow

marat_ezhov@mail.ruФГВУ Национальный медицинский исследовательский центр терапии и профилактической медицины Минздрава РоссииNational Medical Research Center for Therapy and Preventive MedicineФГБУ Национальный медицинский исследовательский центр кардиологии Минздрава РоссииNational Medical Research Center of Cardiology20201411202019525322532Copyright © Близнюк С.А., Бубнова М.Г., Ежов М.В., 20202020Близнюк С.А., Бубнова М.Г., Ежов М.В.Bliznyuk S.A., Bubnova M.G., Ezhov M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/2532

Семейная гиперхолестеринемия является наиболее распространенным наследственным заболеванием, характеризующимся повышением концентрации холестерина липопротеинов низкой плотности и преждевременным развитием сердечно-сосудистых заболеваний атеросклеротического генеза. Диагностика и лечение таких больных сопряжены с определенными трудностями. В данном обзоре приведены данные о распространенности семейной гиперхолестеринемии, рассмотрены особенности выявления больных с подобным диагнозом, профилактики неблагоприятных сердечно-сосудистых событий, обсуждены вопросы назначения гиполипидемической терапии.

Familial hypercholesterolemia is the most common hereditary disease characterized by an increase in low density lipoprotein cholesterol levels and the premature development of atherosclerosis-related cardiovascular diseases. Diagnosis and treatment of such patients are associated with certain difficulties. This review presents data on the prevalence of familial hypercholesterolemia, identification of patients with such a diagnosis, prevention of adverse cardiovascular events, and also discusses the appointment of lipid-lowering therapy.

гетерозиготная семейная гиперхолестеринемияхолестерин липопротеинов низкой плотностигиполипидемическая терапиястатиныheterozygous familial hypercholesterolemialow density lipoprotein cholesterollipid-lowering therapystatinsReferencesNordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478-90. doi:10.1093/eurheartj/eht273.Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478-90. doi:10.1093/eurheartj/eht273.Akioyamen LE, Genest J, Shan SD, et al. Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. BMJ Open. 2017;9(7):e016461. doi:10.1136/bmjopen-2017-016461.Akioyamen LE, Genest J, Shan SD, et al. Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. BMJ Open. 2017;9(7):e016461. doi:10.1136/bmjopen-2017-016461.Ershova AI, Meshkov AN, Bazhan SS, et al. The prevalence of familial hypercholesterolemia in the West Siberian region of the Russian Federation: A substudy of the ESSE-RF. 2017;12(7):e0181148. doi:10.1371/journal.pone.0181148.Ershova AI, Meshkov AN, Bazhan SS, et al. The prevalence of familial hypercholesterolemia in the West Siberian region of the Russian Federation: A substudy of the ESSE-RF. 2017;12(7):e0181148. doi:10.1371/journal.pone.0181148.Nordestgaard BG, Benn M. Genetic testing for familial hyper-cholesterolaemia is essential in individuals with high LDL cholesterol: who does it in the world? Eur Heart J. 2017;38(20):1580-3. doi:10.1093/eurheartj/ehx136.Nordestgaard BG, Benn M. Genetic testing for familial hyper-cholesterolaemia is essential in individuals with high LDL cholesterol: who does it in the world? Eur Heart J. 2017;38(20):1580-3. doi:10.1093/eurheartj/ehx136.Goldstein JL, Brown MS. Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. J Biol Chem. 1974;249(16):5153-62.Goldstein JL, Brown MS. Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. J Biol Chem. 1974;249(16):5153-62.Myant NB. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholestero-laemia. Atherosclerosis. 1993;104(1-2):1-18. doi:10.1016/0021-9150(93)90171-p.Myant NB. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholestero-laemia. Atherosclerosis. 1993;104(1-2):1-18. doi:10.1016/0021-9150(93)90171-p.Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154-6. doi:10.1038/ng1161.Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154-6. doi:10.1038/ng1161.Austin MA, Hutter CM, Zimmern RL, et al. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol. 2004;160(5):407-20. doi:10.1093/aje/kwh236.Austin MA, Hutter CM, Zimmern RL, et al. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol. 2004;160(5):407-20. doi:10.1093/aje/kwh236.Harada-Shiba M, Takagi A, Miyamoto Y, et al. Clinical features and genetic analysis of autosomal recessive hypercholesterolemia. J Clin Endocrinol Metab. 2003;88(6):2541-7 doi:10.1210/jc.2002-021487.Harada-Shiba M, Takagi A, Miyamoto Y, et al. Clinical features and genetic analysis of autosomal recessive hypercholesterolemia. J Clin Endocrinol Metab. 2003;88(6):2541-7 doi:10.1210/jc.2002-021487.Yamamoto T, Davis CG, Brown MS, et al. The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell. 1984;39(1):27-38. doi:10.1016/0092-8674(84)90188-0.Yamamoto T, Davis CG, Brown MS, et al. The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell. 1984;39(1):27-38. doi:10.1016/0092-8674(84)90188-0.Soutar AK, Naoumova R. P. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2007;4(4):214-25. doi:10.1038/ncpcardio0836.Soutar AK, Naoumova R. P. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2007;4(4):214-25. doi:10.1038/ncpcardio0836.Hopkins PN, Defesche J, Fouchier SW, et al. Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody. Circ Cardiovasc Genet. 2015;8(6):823-31. doi:10.1161/CIRCGENETICS.115.001129.Hopkins PN, Defesche J, Fouchier SW, et al. Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody. Circ Cardiovasc Genet. 2015;8(6):823-31. doi:10.1161/CIRCGENETICS.115.001129.Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease 8th ed. New York: McGraw-Hill, 2001:2863-913. ISBN 978-0-071-36321-1.Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease 8th ed. New York: McGraw-Hill, 2001:2863-913. ISBN 978-0-071-36321-1.Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):844-53. doi:10.1093/eurheartj/ehq386.Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):844-53. doi:10.1093/eurheartj/ehq386.Kwiterovich PO, Fredrickson DS, Levy RI. Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974;53(5):1237-49. doi:10.1172/JCI107670.Kwiterovich PO, Fredrickson DS, Levy RI. Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974;53(5):1237-49. doi:10.1172/JCI107670.Langsted A, Kamstrup PR, Benn M, et al. High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study. Lancet Diabetes Endocrinol. 2016;4(7):577-87 doi:10.1016/S2213-8587(16)30042-0.Langsted A, Kamstrup PR, Benn M, et al. High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study. Lancet Diabetes Endocrinol. 2016;4(7):577-87 doi:10.1016/S2213-8587(16)30042-0.Clarke R, Peden JF, Hopewell JC, et al. PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26):2518-28. doi:10.1056/NEJMoa0902604.17 Clarke R, Peden JF, Hopewell JC, et al. PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26):2518-28. doi:10.1056/NEJMoa0902604.Erqou S, Thompson A, Di Angelantonio E, et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol. 2010;55(19):2160-7 doi:10.1016/j.jacc.2009.10.080.Erqou S, Thompson A, Di Angelantonio E, et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol. 2010;55(19):2160-7 doi:10.1016/j.jacc.2009.10.080.Kamstrup PR, Tybj®rg-Hansen A, Steffensen R, et al. Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction. JAMA. 2009;301(22):2331-9. doi:10.1001/jama.2009.801.Kamstrup PR, Tybj®rg-Hansen A, Steffensen R, et al. Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction. JAMA. 2009;301(22):2331-9. doi:10.1001/jama.2009.801.Akioyamen LE, Genest J, Chu A, et al. Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis. J Clin Lipidol. 2019;13(1):15-30. doi:10.1016/j.jacl.2018.10.012.Akioyamen LE, Genest J, Chu A, et al. Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis. J Clin Lipidol. 2019;13(1):15-30. doi:10.1016/j.jacl.2018.10.012.Perez de Isla L, Alonso R, Mata N, et al. Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study). Circulation. 2017; 135(11 ):2133-2144. doi: 10.1161/CIRCULATIONAHA.116.024541.Perez de Isla L, Alonso R, Mata N, et al. Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study). Circulation. 2017; 135(11 ):2133-2144. doi: 10.1161/CIRCULATIONAHA.116.024541.Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 1991;303(6807)893-6. doi:10.1136/bmj.303.6807.893.Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 1991;303(6807)893-6. doi:10.1136/bmj.303.6807.893.Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet. 2001;357(9251):165-8. doi:10.1016/S0140-6736(00)03587-X.Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet. 2001;357(9251):165-8. doi:10.1016/S0140-6736(00)03587-X.Williams RR, Hunt SC, Schumacher MC, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol. 1993;72(2):171-6.Williams RR, Hunt SC, Schumacher MC, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol. 1993;72(2):171-6.Wang J, Dron JS, Ban MR, et al. Polygenic versus monogenic causes of hypercholesterolemia ascertained clinically. Arterioscler Thromb Vasc Biol. 2016;36(12):2439-45. doi:10.1161/ATVBAHA.116.308027Wang J, Dron JS, Ban MR, et al. Polygenic versus monogenic causes of hypercholesterolemia ascertained clinically. Arterioscler Thromb Vasc Biol. 2016;36(12):2439-45. doi:10.1161/ATVBAHA.116.308027Hopkins PN, Lane SR. Genotype-guided diagnosis in familial hypercholesterolemia: clinical management and concerns. Curr Opin Lipidol. 2017;28(2): 144-51. doi: 10.1097/MOL.0000000000000397.Hopkins PN, Lane SR. Genotype-guided diagnosis in familial hypercholesterolemia: clinical management and concerns. Curr Opin Lipidol. 2017;28(2): 144-51. doi: 10.1097/MOL.0000000000000397.Marks D, Wonderling D, Thorogood M, et al. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2000;4(29):1-123. doi:10.3310/hta4290.Marks D, Wonderling D, Thorogood M, et al. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2000;4(29):1-123. doi:10.3310/hta4290.Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455.Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455.Perez de Isla L, Alonso R, Watts GF, et al. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry FollowUp. J Am Coll Cardiol. 2016;67(11):1278-85. doi: 10.1016/j.jacc.2016.01.008.Perez de Isla L, Alonso R, Watts GF, et al. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry FollowUp. J Am Coll Cardiol. 2016;67(11):1278-85. doi: 10.1016/j.jacc.2016.01.008.Garcia-Calvo M, Lisnock HG, Bull BE, et al. The target of ezetimibe is Niemann-Pick C1-like 1 (NPC1L1) Proc Natl Acad Sci. 2005;102(23):8132-7 doi:10.1073/pnas.0500269102.Garcia-Calvo M, Lisnock HG, Bull BE, et al. The target of ezetimibe is Niemann-Pick C1-like 1 (NPC1L1) Proc Natl Acad Sci. 2005;102(23):8132-7 doi:10.1073/pnas.0500269102.Norata GD, Tibolla G, Catapano AL. Targeting PCSK9 for hypercholesterolemia. Annu Rev Pharmacol Toxicol. 2014;54:273-93. doi:10.1146/annurev-pharmtox-011613-140025.Norata GD, Tibolla G, Catapano AL. Targeting PCSK9 for hypercholesterolemia. Annu Rev Pharmacol Toxicol. 2014;54:273-93. doi:10.1146/annurev-pharmtox-011613-140025.Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):331-40. doi:10.1016/S0140-6736(14)61399-4.Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):331-40. doi:10.1016/S0140-6736(14)61399-4.Ginsberg HN, Rader DJ, Raal FJ, et al. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher. Cardiovasc Drugs Ther. 2016;30(5)473-83. doi:10.1007/s10557-016-6685-y.Ginsberg HN, Rader DJ, Raal FJ, et al. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher. Cardiovasc Drugs Ther. 2016;30(5)473-83. doi:10.1007/s10557-016-6685-y.Kastelein JJ, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36(43):2996-3003. doi:10.1093/eurheartj/ehv370.Kastelein JJ, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36(43):2996-3003. doi:10.1093/eurheartj/ehv370.Kastelein JJ, Hovingh GK, Langslet G, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia. J Clin Lipidol. 2017;11(1):195-203. doi:10.1016/j.jacl.2016.12.004.Kastelein JJ, Hovingh GK, Langslet G, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia. J Clin Lipidol. 2017;11(1):195-203. doi:10.1016/j.jacl.2016.12.004.Robinson JG, Farnier M, Krempf M, et al. ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489-99. doi:10.1056/NEJMoa1501031.Robinson JG, Farnier M, Krempf M, et al. ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489-99. doi:10.1056/NEJMoa1501031.Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher. 2016;31(3):149-62. doi:10.1002/jca.21470.37 Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher. 2016;31(3):149-62. doi:10.1002/jca.21470.Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J. 2008;29(21):2625-33. doi: 10.1093/eurheartj/ehn422.Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J. 2008;29(21):2625-33. doi: 10.1093/eurheartj/ehn422.Besseling J, Hovingh GK, Huijgen R, et al. Statins in familial hypercholesterolemia: consequences for coronary artery disease and allcause mortality. J Am Coll Cardiol. 2016;68(3):252-60. doi:10.1016/j.jacc.2016.04.054.Besseling J, Hovingh GK, Huijgen R, et al. Statins in familial hypercholesterolemia: consequences for coronary artery disease and allcause mortality. J Am Coll Cardiol. 2016;68(3):252-60. doi:10.1016/j.jacc.2016.04.054.Ежов М. В., Близнюк С. А., Тмоян Н. А. и др. Регистр пациентов с семейной гиперхолестеринемией и пациентов очень высокого сердечно-сосудистого риска с недостаточной эффективностью проводимой гиполипидемической терапии (РЕНЕССАНС). Российский кардиологический журнал. 2019;(5):7-13. doi:10.15829/1560-4071-2019-5-7-13.Yezhov MV, Bliznyuk SA, Tmoyan NA, et al. Register of patients with familial hypercholesterolemia and patients of very high cardiovascular risk with lipid-lowering therapy underperformance (RENESSANS). Russian Journal of Cardiology. 2019;(5):7-13. (In Russ.) doi:10.15829/1560-4071-2019-5-7-13.Близнюк С. А., Рожкова Т.А., Ежов М. В., и др. Особенности гиполипидеми-ческой терапии и предикторы исходов у больных с семейной гиперхолестеринемией. Атеросклероз и дислипидемии. 2019;37(4):36-45. doi: 10.34687/2219-8202.JAD.2019.04.0004.Bliznyuk SA, Rozhkova TA, Ezhov MV, et al. Lipid-lowering Therapy and Predictors of Outcomes in Patients with heterozygous Familial Hypercholesterolemia. The Journal of Atherosclerosis and Dyslipidemias. 2019;37(4):36-45. (In Russ.) doi: 10.34687/2219-8202.JAD.2019.04.0004.Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376:1430-40. doi:10.1056/NEJMoa1615758.Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376:1430-40. doi:10.1056/NEJMoa1615758.Ray KK, Stoekenbroek RM, Kallend D, et al. Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial. JAMA Cardiol. 2019;4(11):1067-75. doi:10.1001/jamacardio.2019.3502.Ray KK, Stoekenbroek RM, Kallend D, et al. Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial. JAMA Cardiol. 2019;4(11):1067-75. doi:10.1001/jamacardio.2019.3502.Jia X, Virani SS. CLEAR Serenity Trial: More Clarity for the Future of Bempedoic Acid in Patients Unable to Take Statins? J Am Heart Assoc. 2019;8(7):e012352. doi:10.1161/JAHA.119.012352.Jia X, Virani SS. CLEAR Serenity Trial: More Clarity for the Future of Bempedoic Acid in Patients Unable to Take Statins? J Am Heart Assoc. 2019;8(7):e012352. doi:10.1161/JAHA.119.012352.Ray KK, Bays HE, Catapano AL, et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med. 2019;380(11):1022-32. doi:10.1056/NEJMoa1803917Ray KK, Bays HE, Catapano AL, et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med. 2019;380(11):1022-32. doi:10.1056/NEJMoa1803917

The authors declare that there are no conflicts of interest present.